In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Latest From DeveloGen

Appointments: Gyroscope, Urovant, Horizon, Modus, Allied Minds And Adherium

This week's roundup includes CEO appointments by Gyroscope Therapeutics, Urovant Sciences and Nevoii Pharmaceuticals, in addition to various other high-level appointments by companies including, Horizon Pharma, Veloxis Pharmaceuticals, Modus Therapeutics and Adherium.

Executive Changes BioPharmaceutical

Further Sanofi Deals Move Evotec On From Development Setbacks

Evotec has signed two more R&D deals with French major Sanofi that it hopes will help it move on from previous R&D disappointments.

Metabolic Disorders Cancer

Evotec Expands Sanofi Link With Exclusive Stem Cell Diabetes Deal

Evotec’s deal with the French drugmaker to develop stem cell-based treatments for diabetes takes on even more importance following the demise of the biotech’s two lead proprietary candidate therapies.

BioPharmaceutical Germany

Evotec sues Andromeda after DiaPep277 deception

Germany's Evotec has taken legal steps against Israel's Andromeda Biotech in an effort to recoup its losses following Andromeda's falsification of trial results for diabetes drug DiaPep277. Evotec's stock took a dive when the deception came to light earlier in September and has yet to recover.

Metabolic Disorders Israel
See All

Company Information